Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hypoimmune EHM
- Development stage
- Preclinical
- Lead developer
- Sana Biotechnology
- Modality
- Gene Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraportal, Intratumoral, Implantation
01
Overview
Hypoimmune EHM refers to a genetically engineered cell therapy platform designed to evade immune rejection in allogeneic transplantation. The "hypoimmune" approach involves modifying cells—such as induced pluripotent stem cells (iPSCs)—to disrupt expression of major histocompatibility complex (MHC) class I and II molecules, thereby preventing recognition by the adaptive immune system, and overexpressing CD47 to inhibit innate immune responses from macrophages and natural killer (NK) cells. This technology aims to enable off-the-shelf cell therapies without the need for immunosuppression, with potential applications in diseases such as cancer, type 1 diabetes, and regenerative medicine. Sana Biotechnology is a leading developer of this platform.
- Other names
- hypoimmune EHM
02
Targets
SIRPA (Signal-regulatory protein alpha)MHC I (MHC class I})
Beyond the preview
Go deeper on hypoimmune EHM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hypoimmune EHM.